A man smiling and painting a pottery mug he is holding

Proven efficacy across multiple clinical endpoints1

Actor portrayal.

The first phase 3 trials of an orexin receptor 2 agonist in patients with narcolepsy type 1 (NT1) 

Study design 

Two randomized, phase 3, multicenter, double‑blind, placebo-controlled, 12‑week, parallel-group studies in adult patients with NT11

 

Study 1 included patients as young as 16 years of age1

Washout criteria

Monotherapy study: Medications or supplements used for the treatment of NT1 were required to be discontinued prior to study start2

Primary efficacy endpoint 

Change from baseline to week 12 compared with placebo in mean sleep latency from the Maintenance of Wakefulness Test (MWT)1 

Study design

Two randomized, phase 3, multicenter, double‑blind, placebo-controlled, 12‑week, parallel-group studies in adult patients with NT11

Study 1 included patients as young as 16 years of age1

Washout criteria

Monotherapy study: Medications or supplements used for the treatment of NT1 were required to be discontinued prior to study start2

Primary efficacy endpoint 

Change from baseline to week 12 compared with placebo in mean sleep latency from the Maintenance of Wakefulness Test (MWT)1

 Study 1 (FirstLight)1Study 2 (RadiantLight)1
Treatment arms

168 PATIENTS

Placebo twice daily (n=41)

ORZEYFUL 1 mg twice daily (n=61)

ORZEYFUL 2 mg twice daily (n=66)

105 PATIENTS 

Placebo twice daily (n=35) 

ORZEYFUL 2 mg twice daily (n=70) 

Baseline characteristics
  • The mean age was 31 years 
 (range 16 to 65 years of age)
  • 58% were female
  • 35% were White
  • 16% were Asian
  • 4% were Black or African American
  • 8% were of Hispanic or Latino ethnicity
  • The mean age was 31 years 
 (range 18 to 62 years)
  • 48% were female
  • 45% were White
  • 20% were Asian
Treatment arms
Study 1 (FirstLight)1

168 PATIENTS

Placebo twice daily (n=41)

ORZEYFUL 1 mg twice daily (n=61)

ORZEYFUL 2 mg twice daily (n=66)

Study 2 (RadiantLight)1

105 PATIENTS 

Placebo twice daily (n=35) 

ORZEYFUL 2 mg twice daily (n=70) 

Baseline characteristics
Study 1 (FirstLight)1
  • The mean age was 31 years (range 16 to 65 years of age)
  • 58% were female
  • 35% were White
  • 16% were Asian
  • 4% were Black or African American
  • 8% were of Hispanic or Latino ethnicity
Study 2 (RadiantLight)1
  • The mean age was 31 years (range 18 to 62 years)
  • 48% were female
  • 45% were White
  • 20% were Asian

References: 1. ORZEYFUL (oveporexton tablets) prescribing information. Takeda Pharmaceuticals. 2. Data on File. Takeda Pharmaceuticals.

BID=twice a day; CI=confidence interval; ESS=Epworth Sleepiness Scale; FINI=Functional Impacts of Narcolepsy Instrument; LS=least squares; MWT=Maintenance of Wakefulness Test; NSS-CT=Narcolepsy Severity Scale for Clinical Trials; PGI-C=Patient’s Global Impression Scale; PVT=Psychomotor Vigilance Test; SF-36=36-Item Short Form Health Survey; WCR=Weekly Cataplexy Rate.

References: 1. ORZEYFUL (oveporexton tablets) prescribing information. Takeda Pharmaceuticals. 2. Data on File. Takeda Pharmaceuticals. 3. Doghramji K, Mitler MM, Sangal RB, et al. A normative study of the maintenance of wakefulness test (MWT). Electroencephalogr Clin Neurophysiol. 1997;103(5):554-562. doi:10.1016/s0013-4694(97)00010-2 4. Krahn LE, Arand DL, Avidan AY, et al. Recommended protocols for the Multiple Sleep Latency Test and Maintenance of Wakefulness Test in adults: guidance from the American Academy of Sleep Medicine. J Clin Sleep Med. 2021;17(12):2489-2498. doi:10.5664/jcsm.9620

BID=twice a day; CI=confidence interval; ESS=Epworth Sleepiness Scale; FINI=Functional Impacts of Narcolepsy Instrument; LS=least squares; MWT=Maintenance of Wakefulness Test; NSS-CT=Narcolepsy Severity Scale for Clinical Trials; PGI-C=Patient’s Global Impression Scale; PVT=Psychomotor Vigilance Test; SF-36=36-Item Short Form Health Survey; WCR=Weekly Cataplexy Rate.

References: 1. ORZEYFUL (oveporexton tablets) prescribing information. Takeda Pharmaceuticals. 2. Data on File. Takeda Pharmaceuticals. 3. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep. 1991;14(6):540-545. doi:10.1093/sleep/14.6.540 4. Johns M, Hocking B. Daytime sleepiness and sleep habits of Australian workers. Sleep. 1997;20(10):844-849. doi:10.1093/sleep/20.10.844

BID=twice a day; CI=confidence interval; ESS=Epworth Sleepiness Scale; FINI=Functional Impacts of Narcolepsy Instrument; LS=least squares; MWT=Maintenance of Wakefulness Test; NSS-CT=Narcolepsy Severity Scale for Clinical Trials; PGI-C=Patient’s Global Impression Scale; PVT=Psychomotor Vigilance Test; SF-36=36-Item Short Form Health Survey; WCR=Weekly Cataplexy Rate.

References: 1. ORZEYFUL (oveporexton tablets) prescribing information. Takeda Pharmaceuticals. 2. Data on File. Takeda Pharmaceuticals.

BID=twice a day; CI=confidence interval; ESS=Epworth Sleepiness Scale; FINI=Functional Impacts of Narcolepsy Instrument; LS=least squares; MWT=Maintenance of Wakefulness Test; NSS-CT=Narcolepsy Severity Scale for Clinical Trials; PGI-C=Patient’s Global Impression Scale; PVT=Psychomotor Vigilance Test; SF-36=36-Item Short Form Health Survey; WCR=Weekly Cataplexy Rate.

References: 1. ORZEYFUL (oveporexton tablets) prescribing information. Takeda Pharmaceuticals. 2. Data on File. Takeda Pharmaceuticals. 3. Mahoney CE, Cogswell A, Koralnik IJ, Scammell TE. The neurobiological basis of narcolepsy. Nat Rev Neurosci. 2019;20(2):83-93. doi:10.1038/s41583-018-0097-x